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Abstract 16 
Recent reports from Australia suggest that cobalt chloride is being used in racehorses 17 
competing in New South Wales and Victoria. Although these are the first such reports, it is 18 
suspected that cobalt chloride may have been used illegally for some time. Cobalt chloride is 19 
a well-established hypoxia mimetic that is used experimentally to stabilise hypoxia-inducible 20 
factor 1  (HIF-1) at the cellular level. It can induce hypoxia-like responses, increase blood 21 
erythropoietin (EPO) levels, promote erythropoiesis and enhance the oxygen carrying 22 
capacity of blood. However, prolonged administering large quantities of cobalt salts can lead 23 
to serious health problems such as cardiomyopathy. Supraphysiological doses of cobalt 24 
chloride may result in systemic cytotoxicity, myocardial dysfunction and acute inflammatory 25 
responses in the myocardium leading to cardiac arrest and death. In this paper we review the 26 
current evidence for the illicit use of cobalt chloride in racehorses. There are genuine 27 
concerns that non-veterinarians are sourcing misleading information from the internet as 28 
there are websites claiming that cobalt chloride can improve equine health and performance. 29 
It is the duty of veterinary surgeons working in the racing industry to ensure that owners, 30 
trainers and race officials are aware of the dangers of ‘amateur’ use of a potentially fatal 31 
compound. 32 
(202 words in abstract) 33 
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Introduction 37 
Blood doping is an illegal and unacceptable way of enhancing athletic performance by 38 
increasing the oxygen carrying capacity of blood (Lippi et al., 2005). Currently used blood 39 
doping methods usually involve stimulation of erythropoiesis by using erythropoietin (EPO) 40 
or its recombinant form (Debeljak and Sytkowski, 2012). EPO is the hormone responsible for 41 
controlling erythropoiesis in bone marrow therefore erythropoiesis-stimulating agents (ESAs) 42 
and metal salts that can substitute for and simulate the erythropoietic actions of EPO have 43 
been used as potential performance-enhancing agents (Lippi et al., 2006; Duh et al., 2008). 44 
Although these agents may possibly have some physiological effects, there are significant 45 
risks associated with the illicit use of these substances in athletes (Franz, 2009). 46 
 47 
The popular press frequently publishes revelations about the possible use of anabolic 48 
steroids and other banned substances in racehorses. The most recent report comes from 49 
Australia and involves the detection of cobalt chloride in racehorses competing in New South 50 
Wales and Victoria 1. Although these convictions are the first in the country, it is suspected 51 
that cobalt chloride doping may have been practiced for some time. 52 
 53 
Cobalt chloride is a well-established hypoxia mimetic and inducer of hypoxia-like 54 
responses, which can cause gene modulation at the hypoxia inducible factor pathway to 55 
stimulate EPO transcription and increase its levels in blood (Ho et al., 2014). Cobalt (symbol 56 
Co, atomic number 27) is a transition metal in the periodic table. In biological systems cobalt 57 
is at the active centre of coenzymes such as cobalamins, the most common example of which 58 
is vitamin B12. Therefore, cobalt is an essential trace micronutrient that is important for the 59 
formation of the vitamin B12 complex. As an activator of enzymes it is involved in the 60 
                                                 
1 http://www.theage.com.au/sport/horseracing/stewards-find-first-cobalt-chloride-irregularity-
in-victoria-20141204-120dwm.html (accessed 8 March 2015) 
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oxygen-carrying function of red blood cells and can replace the co-factor zinc in some 61 
enzymes. There are no published reports of cobalt dietary deficiency. A variety of foods 62 
including nuts, green leafy vegetables, fish and cereals contain cobalt and it unlikely for 63 
humans to develop dietary deficiencies. 64 
 65 
Currently there is no evidence to suggest that cobalt chloride can enhance human or 66 
equine performance. The rationale for its use in racehorses is likely to be based on preclinical 67 
research done in cell lines and some anecdotal evidence from in vivo studies in laboratory 68 
animals, suggesting that cobalt chloride may have the same effect as EPO on erythropoiesis 69 
in bone marrow. Cobalt chloride is not a prescription medication and various cobalt salts are 70 
available for purchase from a variety of commercial sources. The salts are inexpensive, easily 71 
accessible, not subject to medicines regulation and orally active. Therefore, ill-informed and 72 
unscrupulous trainers can easily obtain cobalt chloride and administer it to horses. However, 73 
regulatory bodies have recently implemented a urinary threshold of 2000 ng/mL and a plasma 74 
threshold of 10 ng/mL for the control of cobalt abuse in non-race day or out-of-competition 75 
samples (200ug/l plasma in Australia and 100ug/l in Hong Kong) (Ho et al., 2014). 76 
 77 
Aside from the lack of evidence for enhanced athletic performance in horses, one of 78 
the key concerns is the paucity of information about the long-term safety of cobalt chloride 79 
administration and toxicity, especially in vital organs. In the US there have been reports of 80 
unexplained deaths in horses that were found to have elevated blood levels of cobalt chloride. 81 
Although cobalt salts have medical applications for the treatment of anaemia (Bowie and 82 
Hurley, 1975; Duckham and Lee, 1976), cobalt can be highly toxic. Cobalt exerts well-83 
known and well-documented neurotoxic effects (Catalani et al., 2012) in addition to its toxic 84 
actions on the thyroid, the heart and the haematopoietic system. High doses of cobalt in 85 
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patients exposed to abnormal levels from damaged hip prostheses induce optic and auditory 86 
neuropathy (Apostoli et al., 2013). Furthermore, there are reports that cobalt exposure may 87 
lead to fatal cardiomyopathy and ischemic heart disease in cobalt-exposed workers (Barborik 88 
and Dusek, 1972; Jarvis et al., 1992; Centeno et al., 1996) and in regular beer drinkers who 89 
have consumed beer from breweries with cobalt contamination (Alexander, 1972). It is also 90 
worth commenting that cobalt-drug interactions are unknown. Racehorses commonly receive 91 
NSAIDs and, in non-UK racing jurisdictions, can race on furosemide medication. 92 
 93 
However, the lay public does not have access to detailed information about the 94 
potential risks and many trainers do not have the scientific knowledge to assess the risk: 95 
benefit ratio for the use of cobalt salts. Unfortunately, the Internet is a source of inaccurate, 96 
conflicting and misleading information about cobalt and its salts. This is the introductory text 97 
that describes uses of cobalt chloride in horses on the eHow website2: 98 
 99 
‘Cobalt chloride, also nicknamed blue salt by the horse and 100 
cattle community, is often associated with the dietary needs of 101 
cows. Cobalt chloride isn't only for cattle, however. Horses can 102 
also benefit from supplements of this essential electrolyte, as 103 
nontraditional as their consumption of it may be. Horse owners 104 
should use caution in dispensing cobalt chloride to avoid 105 
overdoses and unnecessary iodine intake, but there are usually 106 
few risks involved.’  107 
 108 
                                                 
2 http://www.ehow.com/info_8740774_use-cobalt-chloride-equines.html (accessed 8 March 
2015) 
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The author of this non-refereed article is Kirsty Ambrose, a regular contributor to 109 
www.ehow.com. She holds a Bachelor of Arts in English literature from the University of 110 
Victoria and enjoys writing about pet care. Her article is a top hit on Google (5th item in a 111 
Google search (article accessed 8 March 2015) using the keywords ‘cobalt’, ‘chloride’ and 112 
‘equine’). This style of writing clearly gives readers the impression that providing cobalt 113 
chloride to horses can improve their overall health. The paper has not gone any kind of peer-114 
review and the author does not cite any scientific or clinical papers to back up the claim that 115 
‘Horses can also benefit from supplements of this essential electrolyte’. Clearly cobalt is not 116 
a conventional electrolyte. It is a micronutrient and research suggests that micronutrients can 117 
be toxic in high concentrations.  118 
 119 
Medical uses of cobalt and cobalt chloride 120 
It is important to highlight some of the medical uses of cobalt and cobalt chloride. 121 
Cobalt-60 (60Co) is a radioactive form of cobalt used in radiotherapy for targeting inoperable 122 
tumours 3. The concept of 60Co radiotherapy was developed in the 1950’s by scientists at the 123 
University of Saskatchewan in Canada (Johns et al., 1952; Morrison et al., 1952). Although 124 
cobalt therapy has partly been replaced by linear accelerator radiation therapy (the electron 125 
beam), which can generate higher energy radiation, cobalt treatment still has a useful role in 126 
radiotherapy. 60Co is also one of the most commonly used radio-isotopes for food irradiation 127 
4 (Deitch, 1982). 128 
 129 
Cobalt salts have proved to be effective therapies for stimulating erythropoiesis in 130 
both non-renal and renal anaemia. Cobalt chloride has been effective for the management of 131 
uraemic patients with refractory anaemia, especially in patients undergoing long-term 132 
                                                 
3 http://www.epa.gov/radiation/radionuclides/cobalt.html (accessed 8 March 2015) 
4 http://www.epa.gov/radiation/sources/food_irrad.html (accessed 8 March 2015) 
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haemodialysis (Bowie and Hurley, 1975; Duckham and Lee, 1976). Cobalt chloride stabilizes 133 
the transcriptional activator hypoxia-inducible factor 1  (HIF-1) and thus mimics hypoxia 134 
thereby stimulating EPO production (Fig. 1). However, as with any type of drug, there are 135 
also serious medical adverse effects associated with long-term use, especially in high 136 
concentrations. Safe and effective use in the human medical field has been dependent upon 137 
accurate prescribing and diligent monitoring by clinicians for adverse reactions. The same 138 
mechanisms involved in HIF-1 activation may potentially have genotoxic (De Boeck et al., 139 
2003) and carcinogenic (Simonsen et al., 2012) effects, through cobalt mediated inhibition of 140 
DNA repair (Lison et al., 2001). Oral intake of inorganic cobalt salts can cause severe organ 141 
damage, especially by inducing toxicity in the gastrointestinal tract, the thyroid, the heart and 142 
the sensory systems (Ebert and Jelkmann, 2014). These undesirable side effects should deter 143 
professional equine trainers (and human athletes) from using cobalt chloride and other cobalt 144 
salts as ‘chemistry set chemicals’ for stimulating erythropoiesis. 145 
 146 
Cobalt activation of matrix metalloproteinases 147 
Cobalt intake can bear risks to health and the potential effectiveness of cobalt salts 148 
and other ESAs continue to be an open and important question for sport and athletic 149 
regulatory bodies. More research is needed on cobalt physiology and pathophysiology and 150 
more effective strategies are needed to unmask the potentially deleterious effects of cobalt 151 
salts in horses. In vitro studies have demonstrated that cobalt chloride can up-regulate matrix 152 
metalloproteinases 2 and 9 in equine laminar keratinocytes (Medina-Torres et al., 2011). 153 
Cobalt chloride also induces cytotoxicity and upregulates MMP-2 in ligament cells (Song et 154 
al., 2012; Wang et al., 2012). Horses are at risk of developing laminitis and it is possible that 155 
in certain conditions sustained hypoxia within the hoof and up-regulation of MMPs may 156 
cause irreparable damage to the lamellar basement membrane, increasing the risk of laminitis 157 
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(Medina-Torres et al., 2011). Damage to other load-bearing connective tissues is also 158 
potentially possible. These equine-specific risks are currently unquantified. 159 
 160 
Conclusions 161 
Paracelsus the ‘father’ of toxicology wrote: ‘All things are poison and nothing (is) 162 
without poison; only the dose makes that a thing is no poison.’ Clearly, it is the dose that 163 
makes a substance poisonous. To our knowledge studies to determine therapeutic vs. toxic 164 
dose of cobalt chloride in horses have not been published. The schematic in Fig. 2 165 
summarises our concept of therapeutic and supraphysiological doses of hypoxia mimetics. 166 
 167 
Cobalt chloride has pro-apoptotic and anti-apoptotic biphasic effects but these largely 168 
depend on the cell type studied and the dose used. Although low quantities of cobalt chloride 169 
may potentially stimulate erythropoiesis without any lethal effects, we do not have enough 170 
information about the long-term effects of exposing horses to cobalt salts. Cobalt poisoning 171 
can occur following exposure to large amounts of cobalt (Goldfrank, 2011). There are also 172 
genuine concerns about the purity of chemical grade salts that are currently available and 173 
their interactions with other drugs. The cobalt salts currently available are not pharmaceutical 174 
grade substances. High doses of impure cobalt chloride may be associated with significant 175 
toxicity. It is irresponsible and unethical to administer them to horses. 176 
 177 
Therefore, it is important that we continue the development of technologies and 178 
assays to detected and control the misuse of cobalt in horses (Ho et al., 2014) and remain 179 
prepared to review and refine the urinary and plasma threshold concentrations based on 180 
emerging new evidence. If this disturbing trend continues and more unexplained deaths 181 
occur, we must focus new research on the effects of physiologically relevant concentrations 182 
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of cobalt chloride on global patterns of gene expression, protein function and cytotoxicity in 183 
primary equine cells and tissues in vitro, make predictions about its bioavailability and 184 
pathophysiological effects in vivo and develop sensitive biomarkers to examine its effects on 185 
the myocardium. 186 
 187 
The development of new ESAs and the use of cobalt-based chemical agents capable 188 
of acting as hypoxia mimetics and EPO-stimulating agents highlight the need for developing 189 
new and sensitive analytical mass-spectrometry methods for detecting the abuse of these 190 
substances in human sport and horseracing (Reichel, 2011). 191 
 192 
A recent study examined the pharmacokinetics and pharmacodynamics of cobalt 193 
following a single intravenous administration to 18 horses (Knych et al., 2014). The authors 194 
showed that a single intravenous dose of cobalt chloride or cobalt gluconate had no effect on 195 
EPO concentrations, red blood cell parameters or heart rate in any of the horses studied 196 
However, this study did not examine the effects of multiple intravenous doses. We suspect 197 
that this may actually be happening in horseracing. 198 
 199 
We are concerned that some trainers will continue to use Google as the source of 200 
reliable information. It is the duty of veterinary surgeons working in the racing industry to 201 
ensure that trainers are aware of the dangers of ‘amateur’ use of a potentially fatal compound. 202 
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Figure Legends 323 
 324 
Fig. 1: Physiological and pathophysiological regulation of hypoxia-inducible factor 1  (HIF-325 
1) by hypoxia and cobalt chloride. HIF-1 is a basic-helix-loop-helix transcription factor 326 
that activates expression of genes encoding erythropoietin (EPO), glucose transporters 327 
(GLUTs), glycolytic enzymes, vascular endothelial growth factor (VEGF), matrix 328 
metalloproteinases (MMPs) and other genes whose protein products increase oxygen 329 
delivery, facilitate metabolic adaptation to hypoxia (Semenza, 1999, 2000; Sethi et al., 2012). 330 
Cobalt chloride acts as a hypoxia mimetic by activating the expression of genes that contain a 331 
hypoxia response element. Proteasomal pathways degrade HIF-1 during normoxia but this 332 
transcription factor is stabilized under hypoxic conditions and in the presence of hypoxia 333 
mimetics such as cobalt chloride. 334 
 335 
Fig 2: Schematic illustrating the potential effects of high and low doses of hypoxia mimetics 336 
such as cobalt chloride. (A) Low (therapeutic) doses of cobalt chloride may stimulate 337 
erythropoiesis and result in enhanced oxygen carrying capacity. (B) Supraphysiological doses 338 
of cobalt chloride may result in systemic cytotoxicity, myocardial dysfunction and acute 339 
inflammatory responses in the myocardium leading to cardiac arrest and death. 340 
 341 
